Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial save search
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.5 -1.33% -1.35% 370K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $23.28 -2.27% -2.32% 120K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.9 3.48% 3.36% 47K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
Published: 2021-11-23 (Crawled : 13:30) - biospace.com/
APVO 3 d | $0.76 6.67% 6.25% 220K
|
Health Technology
|
| O: 25.38%
H: 132.18%
C: 79.07%
treatment myeloid leukemia phase 1 expansion phase 1b leukemia trial therapeutics apvo436 acute myeloid leukemia phase 2b
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.365 -4.64% -4.86% 470K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $3.03 -5.31% -5.61% 120K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.91 0.58% 0.58% 1.1M
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Published: 2021-01-26 (Crawled : 13:03) - globenewswire.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 1.37%
H: 73.96%
C: 71.96%
hepatitis trial phase 3 phase 1 phase 2 injection ongoing infections chronic hepatitis b
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Published: 2021-03-08 (Crawled : 12:00) - biospace.com/
GLSI | $13.12 0.54% 0.53% 42K
|
Health Technology
|
| O: 0.04%
H: 130.25%
C: 61.67%
cancer breast cancer trial
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
Published: 2023-11-09 (Crawled : 13:30) - biospace.com/
KRBP | $2.3 -90.21% 15K
|
Health Technology
|
| O: 3.96%
H: 53.85%
C: 53.85%
cancer biopharma trial
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial
Published: 2023-02-14 (Crawled : 18:00) - biospace.com/
NMLSF | $0.0083 400.0% 530K
|
n/a
|
| O: -5.51%
H: 49.17%
C: 49.17%
canada health granted trial psilocybin
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
Published: 2021-06-29 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.16 1.35% 1.33% 1.3M
|
Finance
|
| O: 60.38%
H: 54.22%
C: 47.27%
schizophrenia phase 1 positive results topline trial phase 1b phase 2b
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Published: 2022-03-31 (Crawled : 12:00) - globenewswire.com
LGVN | News P 0 d | $2.005 -4.07% -4.24% 990K
|
|
| O: 39.73%
H: 51.65%
C: 46.96%
dementia disease trial results alzheimer’s lomecel-b alzheimer's disease alzheimer's phase 1
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
BIAF | $2.78 -4.47% -4.68% 140K
|
|
| O: 20.13%
H: 108.9%
C: 46.07%
research respiratory trial results publication
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.355 -3.22% -3.33% 830K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
update trial
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
CRDF | $4.355 -3.22% -3.33% 830K
|
Health Services
|
| O: 13.31%
H: 53.5%
C: 45.5%
crdf-004 first cancer trial
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.625 2.2% 2.15% 260K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.625 2.2% 2.15% 260K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.